InvestorsHub Logo
Post# of 252496
Next 10
Followers 4
Posts 332
Boards Moderated 0
Alias Born 12/22/2014

Re: semi_infinite post# 214041

Tuesday, 10/03/2017 5:15:22 PM

Tuesday, October 03, 2017 5:15:22 PM

Post# of 252496
in addition to that you should also read more on the study itself (one of the first links of a google search shows
https://www.dddmag.com/article/2016/04/new-focus-il-12-oncology-research )

as well as look at the competition, both from a scientific standpoint as well as on their financing structure (in case one or two might look more interesting)

TLR 7/9
http://www.dynavax.com <- well, according to a reuters article they will either have outlicensed their HCB vaccine soon or need some kind of (probably?) debt financing to commercialize it & finance their IO-program
http://checkmatepharma.com <- private company
http://www.iderapharma.com <- have not checked financing structure yet
http://www.mologen.com <- personally, I really do not like their financing structure

(certainly not a complete list, but these should be the more known ones)

IL12
http://celsion.com <- have not checked financing structure yet
http://www.inovio.com/products/cancer-vaccines/hpv/cervical-cancer/ <- have not checked financing structure yet
http://oncosec.com <- somewhat ok, but looks to me as if they will need a financing round within a year
http://neumedicines.com <- private company

(it's quite surprising how many trials with IL12 for cancer but also other indications are recruiting ... so this is not a complete list)

many, many more approaches to make cold tumors hot
https://www.noxxon.com <- personally, I really do not like their financing structure
...
...

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.